Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CU-00213
- Development stage
- Preclinical
- Lead developer
- Acurex Biosciences
- Modality
- Small Molecules
01
Overview
CU-00213 is a preclinical-stage small molecule drug candidate being developed by AcureX Therapeutics that targets the CaV3.2 T-type calcium channel. It is designed as a selective inhibitor or modulator of the voltage-dependent T-type calcium channel subunit alpha-1H for the potential treatment of several neurodegenerative conditions, including Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and Frontotemporal Dementia with Tau pathology (FTD-Tau), as well as chronic pain. Developed in collaboration with Stanford University, CU-00213 is engineered to cross the blood-brain barrier to provide disease-altering therapeutic effects. As of the latest pipeline updates, the program is in the lead optimization phase.
02
Targets
Beyond the preview
Go deeper on CU-00213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CU-00213.